NCT06040424进行中（未招募）3 期
Randomized, Parallel Group, Phase III, Non-inferiority Study Comparing Ipratropium / Levosalbutamol Fixed Dose Combination in pMDI Form and Ipratropium and Salbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD)
Neutec Ar-Ge San ve Tic A.Ş1 个研究点 分布在 1 个国家目标入组 74 人开始时间: 2023年9月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 74
- 试验地点
- 1
- 主要终点
- FEV1 area under the curve from 0-8 h (FEV1 AUC 0-8 h)
研究概览
简要总结
The goal of this clinical trial is to compare the acute bronchodilator effect of pMDI formed Ipratropium / Levosalbutamol 20 mcg / 50 mcg fixed dose combination or pMDI formed Salbutamol 100 mcg Inhaler and Ipratropium 20 mcg Inhalation Aerosol in combination in stable moderate-severe-very severe COPD patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged 40 years and older who have been newly diagnosed or followed up with a diagnosis of COPD.
- •Stable moderate-severe-very severe COPD patients with a post-bronchodilator FEV1/FVC ratio <70% and a postbronchodilator FEV1 value <80% at the screening visit will be included in the study.
- •Symptom status such as chronic cough, sputum production, and progressive dyspnea with the BCSS (Breathlessness, Cough and Sputum Scale) Index will be evaluated, and the COPD staging of the patient with CAT (COPD Assessment Test) and the severity of dyspnea with mMRC (Modified Medical Research Council) will be determined.
- •Patients with at least 10 pack/year smoking status or smoking history (patients who have quit smoking for at least 6 months or more are defined as ex-smokers).
- •Patients who have not experienced an exacerbation in the previous 4 weeks.
- •If the study participant is female; women using appropriate contraception (pregnancy test will be performed at screening visit).
- •Patients with the ability to communicate with the investigator.
- •Patients who accept to comply with the protocol.
- •Patients who sign written informed consent form.
排除标准
- •History of hypersensitivity to anticholinergics or SABAs (short acting beta agonist).
- •History of COPD exacerbation or lower respiratory track infection that required treatment with antibiotic, oral or parenteral corticosteroid within the last 3 days prior the screening visit or during the run-in/wash-out period or history of respiratory tract infection that required treatment with antibiotic within the last 14 days prior the screening visit.
- •Hospitalization due to COPD or pneumonia within the last 3 mounts prior the screening visit.
- •SGOT (serum glutamic-oxaloacetic transaminase) >80 IU/L, SGPT (serum glutamic-pyruvic transaminase) >80 IU/L, bilirubin >2.0 mg/dL or creatinine >2.0 mg/dL.
- •History of asthma, significant chronic respiratory diseases (i.e., significant bronchiectasis, interstitial lung diseases, etc.) other than COPD or presence of disease that may be serious and/or potentially affect results of the study.
- •Use of beta-blocker, monoamine oxidase (MAO) inhibitor or tricyclic antidepressant within the last 30 days prior the screening visit
- •Recent (within ≤3 months prior the screening visit) history of heart attack, heart failure, acute ischemic heart disease or presence of serious cardiac arrhythmia requiring drug treatment.
- •Regularly use of daytime CPAP (continuous positive airway pressure) oxygen therapy for longer than 1 hour per day.
- •Initiation of pulmonary rehabilitation within the 3 months prior the screening visit.
- •History of lung volume reduction surgery
- •Drug or alcohol abuse
- •Presence of active tuberculosis
- •History of atopy or allergic rhinitis
- •Presence of active cancer
- •Attenuated live virus vaccination within the last 2 weeks prior the screening visit or during the run-in/wash-out period
- •Pregnancy or lactation
- •Presence of known symptomatic prostatic hypertrophy requiring treatment
- •Presence of known narrow-angle glaucoma requiring treatment
- •Currently participating in another clinical trial or treatment with another investigational study drug within the last month or 6-half-lives, whichever is longer.
研究组 & 干预措施
Ipratropium / Levosalbutamol Fixed Dose Combination
Experimental
In this one-day study, patients will be administered 2 inhalation of "İPRALEV 20 mcg/50 mcg aerosol inhalasyonu, süspansiyon" at morning.
干预措施: Ipratropium / Levosalbutamol Fixed Dose Combination (Combination Product)
Ipratropium + Levosalbutamol Free Dose Combination
Active Comparator
In this one-day study, patients will be administered 2 inhalations of "VENTOLİN İnhaler 100 mcg" and then 2 inhalations of "ATROVENT MDI 0,02 mg/dose" at morning.
干预措施: Ipratropium + Levosalbutamol Free Dose Combination (Drug)
结局指标
主要结局
FEV1 area under the curve from 0-8 h (FEV1 AUC 0-8 h)
时间窗: 8 hours
Change From Baseline in Forced Expiratory Volume in one second (FEV1) Area Under the Curve (AUC) 0-8h.
次要结局
- FVC AUC 0-3 h(3 hours)
- FEV1 AUC 3-6 h(3 to 6 hours)
- FEV1 AUC 6-8 h(6 to 8 hours)
- FVC AUC 6-8 h(6 to 8 hours)
- FVC AUC 0-8 h(0 to 8 hours)
- Mean Maximum Change From Baseline in FEV1 and FVC within the first 1 hours after dosing (mL)(Baseline, 1 hours post-dose at treatment day)
- The Time to Onset of Bronchodilator Response(Baseline, 0 to 8 hours post-dose at treatment day)
- FEV1 area under the curve from 0-3 h (FEV1 AUC 0-3 h)(3 hours)
- FVC AUC 3-6 h(3 to 6 hours)
- Change From Baseline in FEV1 and FVC within the first 30 minutes after dosing (mL)(Baseline, 30 minutes post-dose at treatment day)
- Evaluation of Safety(Baseline, 0 to 24 hours post-dose)
- Mean Maximum Change From Baseline in FEV1 and FVC over a period of 8 hours (mL)(Baseline, 0 to 8 hours post-dose at treatment day)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable Chronic Obstructive Pulmonary Disease (COPD) PatientsCOPDNCT05890638Neutec Ar-Ge San ve Tic A.Ş74
已完成
2 期
Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02260011Boehringer Ingelheim41
已完成
4 期
Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPDCOPDNCT02541006Neutec Ar-Ge San ve Tic A.Ş58
已完成
2 期
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.Pulmonary Disease, Chronic ObstructiveNCT00528996Boehringer Ingelheim2,080
已完成
2 期
A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThalerAsthmaNCT02148120Chiesi Farmaceutici S.p.A.60